euro-gastroenterology-clinical-pharmacy-2019-tracks

29 / 29

Euro Gastroenterology 2019 & Clinical Pharmacy 2019 Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
Page 53
March 25-26, 2019 | Amsterdam, Netherlands
&
GASTROENTEROLOGY AND HEPATOLOGY
4th International Conference on
CLINICAL PHARMACY & PHARMACY PRACTICE
9th World Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
EVALUATION OF RISK FACTOR ASSOCIATEDWITH DRUG-RESISTANT
TUBERCULOSIS IN YEMEN: THE RESULT FROM GOVERNANCE WITH A HIGH
RATE OF DRUG RESISTANCE
Ammar Ali Saleh Jaber
Universiti Sains Malaysia, Malaysia
Background: Although the world health organization reported Yemen to consider to have low burden drug re-
sistance, this is due to the high shortage of diagnostic method and drug treatment regimen available in Yemen.
Therefore our study aimed to evaluate the risk factor associated Drug Resistance Tuberculosis (DR-TB) and to
identify the shortage in TB management.
Method: In this prospective study, 115 DR-TB patients enrolled in drug resistance program in four major TB
centers in Yemen between January 2014 until December 2016. All patients were followed, and the treatment
outcome was reported.
Result: A total of 135 patients with drug-resistant TB were registered in the four main TB centers in Yemen. Most
patients were from Aden TB center (35.17%). The end of treatment reported a success rate of 77.4 %. Majority
of patients were resistant to one drug (43.5%). 30 patients (26.1%) were resistant to two drugs, 21 % patients
(18.3%) were resistant to two drugs. 21 patients (18.3%) were resistant to 3 drugs. 14 patients (12.2%) were resis-
tant to 4 drugs. A total of 30 patients (26.1%) reported one or more adverse events during the intensive phase
of treatment. In the multivariate logistic regression analysis, revealed that comorbidity (p-value = 0.049, AOR =
4.73), base lungs cavity (p-value = 0.016, AOR = 25.09), abnormal level of creatinine level (p-value = 0.031, AOR
= 4.1), positive culture end of intensive phase (p-value = 0.009, AOR = 8.83) were associated with unsuccessful
treatment outcome of drug resistance patients.
Conclusion: A low success rate of 74% was achieved at the end of treatment. Therefore, the study has not
achieved the success rate set out in goals of stop TB strategies (75%), end TB strategy (90%) and the United
National Sustainable Development Goals (80%). Considering the risk factor associated with DR-TB in Yemen is
essential because it may increase the success rate especially in the high shortage of unavailability of second-line
treatment or lab diagnostic method.
Ammar Ali Saleh Jaber, Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C1-023
Ammar Ali Saleh Jaber has completed his PhD fromUniversiti Sains Malaysia. Currently, he is a lecturer in Universiti Sains
Malaysia. He completed his bachelor’s degree from Rajiv Gandhi University of Health Science and master’s degree from
Jamia Hamdard University in India. He is a member of the Pharmacy Council of India. He works as a pharmacy lecturer
in Lebanese International University for three years and is the head of the clinical pharmacist in Yemen International
Hospital for one year. He has published more than 6 papers in reputed journals.
BIOGRAPHY